Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT04437329
Phase
PHASE3
Sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Docetaxel, nedaplatin, fluorouracil
  • Docetaxel, cisplatin, fluorouracil
  • Nedaplatin
  • Cisplatin
  • Intensity modulated-radiotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III
  • Original clinical staged as III-IVa (except T3-4N0) according to the 8th edition American Joint Committee on Cancer staging system
  • No evidence of distant metastasis (M0)
  • Age between 18-65

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →